

1 MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS ORAL VACCINE
2 AND METHODS

3 Background of the Invention

4 (1) Field of the Invention

5 The present invention relates generally to vaccines and, more particularly, to a method
6 and vaccine for inducing mucosal immunity and a method for generating the vaccine.

7 (2) Description of the Prior Art

8 Both killed and live vaccines have used parenteral administration to achieve
9 immunological protection against pulmonary pathogens: prime examples being influenza A
10 vaccines and BCG. The efficacy of parenteral administration has obscured the pathogenesis of
11 these disease entities. While the lung is the portal of infection, disease is contingent upon
12 systemic dissemination.

13 Parenteral route of vaccination is primarily modeled after the demonstrated ability of
14 BCG to alter the progression of Mycobacterium tuberculosis infection to its pulmonary disease
15 state. The portal infection is the lung. The site of primary infection is also the lung. What is
16 poorly perceived is that pulmonary M. tuberculosis infection is due to hematogenous
17 dissemination. Inhalation acquisition primarily involves the superior segment of the lower lobes
18 or the right middle lobe. Gohn complexes occur in the lymphatic drainages of these sites of
19 infection. Upper lobe disease is the consequence of bacilleemia and metastatic implantation,
20 which accounts for the success of IgG immunoglobulins and systemic T-cell immunity in
21 precluding or arresting the development of metastatic disease in the upper lobes.

1 With *Mycobacterium avium* subspecies *paratuberculosis* (MAP), the portal of infection is
2 the gastrointestinal tract. The target organ is the gastrointestinal disease; however
3 gastrointestinal histopathology does not require a phase of systemic dissemination.

4 Mucosal local humoral immunity is mediated primarily by the IgA class of
5 immunoglobulins. IgG specific antibodies do function in a secondary manner within mucosal
6 immunity. What parenteral killed and live MAP vaccines have demonstrated is that IgG specific
7 antibodies, in concert with transported T-cell response can impact locally on the magnitude of
8 fecal shedding and systemically prolong the interim between established mucosal infection and
9 Johne's disease. The importance of local immunity for mycobacteria is inferred by the
10 observation that immunization of guinea pigs with vaccines directed against hsp60 of
11 *Mycobacterium tuberculosis* did not preclude the development of necrotizing bronchiolitis when
12 a hsp60 heat shock protein of *M. tuberculosis* was applied to the traditional portal of infection.

13 Drawing parallels between *Mycobacterium tuberculosis* and MAP, it is presumed that
14 some cows with either Phase I and II infection may self-cure. Work done in conjunction with the
15 Department of Pathobiology at the University of Florida, College of Veterinary Medicine has
16 suggested that self-cure may occur in cows with Phase III disease. A cow with culture and
17 serologically documented clinical Johne's disease was being serial bleed to obtain high titer sera.
18 Prior to euthanasia, the animal ceased having diarrhea and began gaining weight. At necropsy,
19 the gastrointestinal tract was basically normal. A rare histological section demonstrated MAP.

20 Disease, as opposed to infection, is often a titration between infectious inoculum,
21 organismal virulence and host immune response. If the inoculum dose is controlled and
22 organismal virulence is altered, it is reasonable to assume that the probability of host immunity

1 prevailing is enhanced. With a live oral vaccine, prolonged immunological memory is more
2 likely despite infection containment.

3 The failure of both live and killed, parentally administered, MAP vaccines to preclude
4 ultimate disease turns the focus of investigation to the importance of local immunity induction
5 within the target organ. A need exists for a vaccine that is effective in preventing disease at the
6 portal of infection/target organ.

7 Summary of the Invention

8 The present invention is directed toward a method of orally immunizing a host animal
9 against a gastrointestinal or enteric, mucosally invasive organism, specifically *Mycobacterium*
10 *avium* subspecies *paratuberculosis* (MAP). The method steps include providing an enteric,
11 mucosally-adherent, non-systemically invasive, *Mycobacterium avium* subspecies
12 *paratuberculosis* organism and orally administering the MAP organism to a host organism in an
13 immunizing dose and manner.

14 The present invention is also directed toward a method of generating a gastrointestinal,
15 mucosally adherent, non-systemically invasive, live mucosal vaccine organism. The method of
16 generating the vaccine organism includes selecting one or more mucosa-adherent organism strain
17 based on desired binding affinity to an animal species' gastrointestinal tract; serially passaging
18 the at least one strain in culture sufficient to significantly alter genomic expression; monitoring
19 the passages for adherence to the mucosa of interest; demonstrating in-vivo alteration of the
20 pathogenicity, including the mucosal histopathogenicity, and non-systemic invasiveness of the at
21 least one passaged strain; and testing for the ability of the at least one passaged strain to confer
22 protection against mucosal challenge by wild MAP strains.

1 The present invention is further directed towards a mucosal vaccine against an oral
2 *Mycobacterium avium* subspecies *paratuberculosis*, consisting of a mucosally adherent, non-
3 invasive, *Mycobacterium avium* subspecies *paratuberculosis* organism and a pharmaceutically
4 acceptable carrier.

5 Accordingly, one aspect of the present invention is to provide a method of orally
6 immunizing a host organism against a gastrointestinal or enteric, mucosally invasive organism,
7 specifically *Mycobacterium avium* subspecies *paratuberculosis*, the method steps including
8 providing an enteric, mucosally-adherent, non-systemically invasive, *Mycobacterium avium*
9 subspecies *paratuberculosis* organism and orally administering the MAP organism to a host
10 organism in an immunizing dose and manner.

11 Another aspect of the present invention is to provide a method of generating a
12 gastrointestinal, mucosally adherent, non-invasive, live mucosal vaccine organism, including
13 selecting at least one mucosa-adherent organism strain based on desired binding affinity to an
14 animal species' gastrointestinal tract; serially passaging the at least one strain in culture
15 sufficient to alter genomic expression; monitoring the passages for adherence to the mucosa of
16 interest; demonstrating in-vivo alteration of mucosal histopathogenicity, and absence of systemic
17 invasiveness of the at least one passaged strain; and testing for the ability of the at least one
18 passaged strain to confer protection against mucosal challenge.

19 Still another aspect of the present invention is to provide an orally administered mucosal
20 vaccine against *Mycobacterium avium* subspecies *paratuberculosis*, consisting of a mucosally
21 adherent, non-systemically invasive, *Mycobacterium avium* subspecies *paratuberculosis*
22 organism and a pharmaceutically acceptable carrier.

1 These and other aspects of the present invention will become apparent to those skilled in
2 the art after a reading of the following description of the preferred embodiment when considered
3 with the drawings.

4 Brief Description of the Drawings

5 Figure 1 is a graph showing divergent intestinal attachment affinity of 5 different MAP
6 strains.

7 Figure 2 is a graph relatively equivalent intestinal attachment of 5 different MAP strains
8 within the gastrointestinal tract.

9 Figure 3 is a graph showing the effect of passage on intestinal attachment affinity of 3
10 different MAP strains.

11 Figure 4 is a graph showing the effect of passage on intestinal attachment location of 3
12 additional different MAP strains.

13 Figure 5 is a graph showing the effect of fibronectin treatment on intestinal attachment
14 affinity of 3 different MAP strains.

15 Figure 6 is a graph showing the effect of fibronectin treatment on divergent intestinal
16 attachment location of 3 different MAP strains.

17 Figure 7 is a histological photomicrograph of a sample of tissue from the colon
18 confirming mucosal presence of MAP.

19 Figure 8 is a histological photomicrograph of a sample of tissue from the lower ileum
20 confirming the presence of MAP within a goblet cell.

21 Detailed Description of the Preferred Embodiments

1 In the following description, like reference characters designate like or corresponding
2 parts throughout the several views. Also in the following description, it is to be understood that
3 such terms as “forward,” “rearward,” “front,” “back,” “right,” “left,” “upwardly,”
4 “downwardly,” and the like are words of convenience and are not to be construed as limiting
5 terms. Referring to the figures in general, the graphs are for the purpose of demonstrating the
6 characteristics of a preferred embodiment of the invention and are not intended to limit the
7 invention thereto.

8 The present invention is directed toward a method of orally immunizing a host organism
9 against a gastrointestinal or enteric, mucosally invasive organism, specifically *Mycobacterium*
10 *avium* subspecies *paratuberculosis* (MAP). The method steps include providing an enteric,
11 mucosally-adherent, non-systemically invasive, *Mycobacterium avium* subspecies
12 *paratuberculosis* organism and orally administering the MAP organism to a host organism in an
13 immunizing dose and manner.

14 The MAP organism preferably stimulates a Th1-type response and elicits IgA secretion
15 and a CMI response. The MAP is preferably a viable organism, although a killed organism may
16 be used. In the case of a killed organism, the organism is killed using non-protein denaturing
17 means, such as lethal irradiation, such as UV-irradiation, gamma-irradiation, particle-beam
18 irradiation, and the like. The MAP may also be a recombinant organism carrying immunogenic
19 genes from other pathogens.

20 The present invention is also directed toward a method of generating a gastrointestinal,
21 mucosally adherent, non-invasive, live mucosal vaccine organism. The method of generating the
22 vaccine organism includes selecting at least one mucosa-adherent organism strain based on
23 desired binding affinity to an animal species' gastrointestinal tract; serially passaging the at least

one strain in culture sufficient to alter genomic expression; monitoring the passages for adherence to the mucosa of interest; demonstrating in-vivo attenuation of the pathogenicity, including the mucosal histopathogenicity, and invasiveness of the at least one passaged strain; and testing for the ability of the at least one passaged strain to confer protection against mucosal challenge.

The animal species for which a vaccine according to the present invention can be developed and administered include all those that can be infected through the gastrointestinal mucosa, more specifically all those that can be infected by MAP through the gastrointestinal mucosa.

The method of generating a vaccine can also include the use of mutagens in culture to increase the mutation frequency of the at least one strain. Additionally, the method can also include monitoring for pathogenicity and/or invasiveness in cell culture prior to in vivo testing.

The present invention is further directed towards a mucosal vaccine against an oral *Mycobacterium avium* subspecies *paratuberculosis*, consisting of a mucosally adherent, non-invasive, *Mycobacterium avium* subspecies *paratuberculosis* organism and a pharmaceutically acceptable carrier.

The MAP organism preferably stimulates a Th1-type response and elicits IgA secretion and a CMI response. The MAP is preferably a viable organism, although a killed organism may be used. In the case of a killed organism, the organism is killed using non-protein denaturing means, such as lethal irradiation, such as UV-irradiation, gamma-irradiation, particle-beam irradiation, and the like. The MAP may also be a recombinant organism carrying immunogenic genes from other pathogens.

1 The present invention includes a method of orally immunizing a host organism against a
2 gastrointestinal, or enteric, mucosally invasive organism, specifically *Mycobacterium avium*
3 subspecies *paratuberculosis* (MAP). The MAP organism is preferably one that targets the
4 intestinal mucosa as the target organ. The immunization method steps include providing an
5 enteric, mucosally-adherent, non-systemically invasive, *Mycobacterium avium* subspecies
6 *paratuberculosis* organism and orally administering the MAP organism to a host organism in an
7 immunizing dose and manner.

8 The vaccine organism will preferably have the following characteristics in order to
9 achieve immunization according to the present invention: a) retained mucosal adherence to MAP
10 receptor sites within the GI tract; b) organism tissue invasion is limited to the mucosal portion of
11 GI tract; c) non-systemically invasive; d) mucosal and serum cytokine pattern and character of
12 lesions induced differ from those created by wild strains; e) mucosal cytokine pattern and
13 histopathology characteristics indicative of a Th1 response; and f) the immunity elicited, either
14 alone or in conjunction with parenteral MAP sub-fraction vaccines, will withstand wild-type
15 strain challenge.

16 Retained mucosal adherence to MAP receptor sites within the GI tract.

17 Mucosal adherence is a prerequisite for mucosal internalization. This fact is substantiated
18 by the failed attempts to induce immunity using heat-killed MAP orally administered vaccines.
19 If the attachment piece is damaged or non-existent, such as by heat-denaturation, internalization
20 will be significantly impaired.

21 Organism tissue invasion is limited to the mucosal portion of GI tract – Non-systemic
22 Invasiveness.

23 Although the vaccine organism is non-systemically invasive, the vaccine organism can

1 invade the mucosa of the GI tract. An oral live MAP vaccine needs to achieve limited mucosal
2 penetration to elicit long-term immunological memory. With other mycobacterium infections,
3 like that produced by *M. tuberculosis*, recovery from disease is not totally predicated on total
4 organismal drug eradication. Ultimate organismal control is achieved by the host immune
5 system. Drug therapy serves primarily to reduce organismal mass to quantum governable by
6 host immunity. Immune deficiency syndromes have demonstrated that viable organism can
7 persist in a static relationship with prior disease site. By genetic modification of virulence and
8 control of immunizing dose, oral MAP vaccines can engender a sufficiently effective Th1
9 response to achieve arrestment of organismal replication within the target organ and yet
10 stimulate long term immunological memory.

11 Mucosal and serum cytokine pattern and character of lesions induced differ from those created
12 by wild strains.

13 With Th2 immune response induction, intra-macrophage replication of MAP
14 predominates and live organisms are disseminated by macrophages within portions of the
15 reticulo-endothelial system, the so-called lepromatous lesion phase, which correlates with MAP
16 serological responsiveness. The initial phase of MAP invasion stimulates a predominantly Th1
17 response which histologically is characterized by presence of lymphocytes as opposed to a Th2
18 characteristic lesion in which epithelioid cells/macrophages predominate. MAP organisms are
19 comparatively rare within a Th1 correlating lesion in contrast to their relative abundance within
20 macrophages when cytokine pattern are consistent with a progressive Th2 response,

21 Mucosal cytokine pattern and histopathology characteristics indicative of a Th1 response.

22 Th1 and Th2 responsiveness to MAP experimental infection tend to have characteristic
23 predominance of a specific type of histological lesion as discussed above.

1 The MAP organism preferably stimulates a Th1-type response and elicits IgA secretion
2 and a cell-mediated immune response. The vaccine organism will also preferably cause
3 organismal histopathology in the host GI tract characteristic of a Th1 response.

4 The immunity elicited, either alone or in conjunction with parenteral MAP sub-fraction vaccines,
5 will withstand wild-type strain challenge.

6 Local immunity can be potentially overwhelmed by progressively increasing the size of
7 the challenge dose. Parenteral administration of killed MAP vaccines contribute to local
8 mucosal immunity as demonstrated by prolongation of time to disease and reduced fecal
9 organismal shedding in vaccinated cows. Once the upper limit of wild MAP challenge is
10 established, a decision as to the need or desirability of a combined oral and parenteral MAP
11 vaccination approach to infection containment can be assessed.

12 The present invention is also directed toward a method of generating a gastrointestinal,
13 mucosally adherent, non-invasive, live mucosal vaccine organism. The method of generating the
14 vaccine organism includes selecting at least one mucosa-adherent organism strain based on
15 desired binding affinity to an animal species' gastrointestinal tract; serially passaging the at least
16 one strain in culture sufficient to alter genomic expression; monitoring the passages for
17 adherence to the mucosa of interest; demonstrating in-vivo attenuation of the pathogenicity,
18 including the mucosal histopathogenicity, and invasiveness of the at least one passaged strain;
19 and testing for the ability of the at least one passaged strain to confer protection against mucosal
20 challenge.

21 The method of generating a vaccine can also include the use of mutagens in culture to
22 increase the mutation frequency of the at least one strain.

1 Work done by the inventor has shown that specific receptors for MAP exist within the
2 bovine gastrointestinal tract, that they involve fibronectin, that they are relatively uniformly
3 distributed within the bovine gastrointestinal, that different strains of MAP have different
4 binding affinities, and that persistence of mucosal binding can be preserved despite attenuation
5 of selected oral vaccine candidates.

6 Basic Methodology:

7 MAP Strains: Five strains of MAP were used in the pending publications: ATTC49164
8 (Strain A; Isolate from a patient with Crohn's disease), ATCC43015 (Strain B; Isolate from a
9 patient with Crohn's disease), ATCC19698 (Strain C - isolate from a cow with naturally
10 acquired paratuberculosis, MAP 728 (Strain E - a passage 10 of a clinical isolate) and MAP 7283
11 (Strain F - a passage 543 of a clinical isolate).

12 Culture Methodology: A bacteriological loop was used to transfer the organisms to a
13 50ml cell culture flask containing 30ml of 7H9 broth with glycerol (Remel, Lenexa, KS). S35
14 Methionine (Trans35S-Label; ICN Biomedical, INC. Irvine, Ca) was added at a concentration of
15 8uCi per ml. All flasks were labeled appropriately and placed in a 37o C, 5% CO2 incubator for
16 three weeks.

17 Calves and animal husbandry

18 Experimental Animals: Animal use protocols were reviewed and approved by the
19 University of Florida Institutional Animal Care and Use Committee in accordance with the
20 Guide for the Care and Use of Laboratory Animals. Four male Holstein calves approximately 2
21 to 4 days old were obtained from a farm in North Florida. Calves were obtained as needed and
22 were housed overnight in the food animal barn at the College of Veterinary Medicine where they

1 were supplied with bedding and water. Calves were sacrificed via electrocution using standard
2 practices in the College of Veterinary Medicine necropsy suite. Two calves were used in the
3 attachment assays.

4 Necropsy and Tissue Preparation: After the calves were sacrificed, each was placed on
5 the necropsy table, the abdomen was opened, and full section strips of the bovine intestine were
6 obtained aseptically through standard necropsy techniques. The intestines were washed with
7 sterile saline to remove fecal material and placed in whirl bags on ice for transport to the
8 laboratory. Strips were dampened with saline to prevent drying. In the laboratory, the strips
9 were washed again with saline to remove any remaining feces, the strips were cut to the proper
10 size, placed in labeled petri dishes, a Teflon insert with a rectangle cut taken from the center was
11 placed in each petri dish to hold the tissue flat. Organ cultures were established from the lower-
12 ileum, mid-ileum, upper-ileum, mid-jejunum, and the colon.

13 Attachment Procedure: The radiolabeled strains of MAP (strains A, B, C, E, and F)
14 were scraped from each of the 50ml cell culture flasks, concentrated by centrifugation, and the
15 pellets washed three times with sterile saline. Pellets were then suspended in 15ml of RPMI-
16 1640 with L-Glutamine (BioWhittaker, Walkersville, MD) and 10% fetal calf serum and
17 sonicated for two minutes to break up clumps. After sonication, the organism were pushed
18 through a 21 gauge needle to break up the remaining clumps and then the concentrated
19 organisms were added to 110ml of RPMI with 10% fetal calf serum to total a total volume of
20 125ml. A sample of each strain of organism was taken and quantitative cultures done by serial
21 dilution and plating on 7H11 agar (Remel, Lenexa, KS). An additional sample was taken to
22 determine the disintegrations per minute (DPM) for the same size sample as that used for the
23 quantitative cultures. This allowed us to determine the labeling efficiency for each strain of

MAP. Twenty-five ml of RPMI solution containing the radiolabelled organisms was placed in each of the five petri dishes containing the different gut sections. This was done for all MAP strains in respectively labeled petri dishes with the gut sections. The petri dishes were then placed in a 37°C, 5% CO₂ incubator on an adjustable reciprocating orbital shaker for three hours. At the end of the incubation period, the strips of the intestine were washed three times with saline removing any unattached organisms. Three punches from each strip were taken from the center of each strip using a 6mm Miltex dermal biopsy punch to ensure that a constant size volume was taken and that edge effects were avoided. Punches were placed in labeled scintillation vials containing 3ml of Wallac Optisolv solubilizer and vials were placed in the 37°C, 5% CO₂ incubator overnight. Scintillation fluid (Wallac Optiphase Highsafe 3) was added to the scintillation vials and they were placed in scintillation racks for counting. The amounts of the organisms that bound to the intestine organ cultures were quantitated by scintillation counting to detect the ³⁵S methionine for 30 minutes per sample. DPMs per standard area were recorded and converted to CFUs by calculating the labeling efficiency of each strain of MAP on the day of the experiment and converting the DPM to CFU via multiplication of the ratio of CFU/DPM.

A full-length strip of tissue was cut from the remaining tissue, rolled so that the lumen could be fully visualized, placed in tissue cassettes, preserved in 10% buffered formalin, and prepared for histological sections via standard methods.

Fibronectin Treatment Attachment Procedure: Because we were mainly interested in how clinical isolates could be affected by coating with fibronectin, and we could not perform these assays using all strains of MAP, we used only three strains of MAP for these experiments. We used strains B, E, and F because strain B comes from a Crohn's disease patient, and strains E and

1 F are low and high in vitro passage clinical isolates from cattle. The same procedure was
2 followed as described previously except after the last wash of the different strains, the organisms
3 were each split into two aliquots. One aliquot of each strain was suspended in 800ul phosphate
4 buffered saline (PBS) and the other half was suspended in 800ul 0.1% fibronectin solution from
5 bovine plasma (Sigma-Aldrich Co., St. Louis, MO). These solutions were then sonicated as
6 described previously and incubated for 1 hour at 37oC in a 5%CO2 incubator.

7 Histology: The tissues were processed for paraffin embedding and sections cut for H&E,
8 Brenn and Brown, and Acid Fast stains. These sections were examined by light microscopy to
9 determine whether or not the tissue appeared normal and to localize the organisms in relation to
10 tissue landmarks.

11 Statistical Analysis: Statistical analyses to detect differences in the attachment of the
12 different strains of MAP to the different sections of the intestine as well as fibronectin treated
13 versus non-fibronectin treated MAP were analyzed by a two-way analysis of variance
14 (ANOVA). Strains (ATCC49164, ATCC43015, ATCC19698, UF7283B, and UF7283)
15 attachments to the following five different regions were studied. Strains with fibronectin
16 treatment (ATCC43015, UF7283B, and UF7283) versus the control of non-fibronectin
17 organisms in PBS (ATCC43015, UF7283B, and UF7283) were analyzed. When ANOVA
18 indicated a significant difference among groups, a Bonfererroni/Dunn multiple mean comparison
19 was also performed to determine which groups were different. Statistics were performed using
20 Microsoft Excel software (Microsoft, Redmond, Washington) and Statview software (SAS
21 institute, Cary, NC).

22 Demonstration of MAP Receptors within the Bovine Gastrointestinal Tract:

Results for this attachment study can be seen in figures 1 through 8. The labeling efficiencies for the different strains of the MAP varied among strains. By this it is meant that the CFU/DPM ratio determined through plating each strain compared with the DPMs given for each strain varied (i.e., some strains incorporated more radioactive material then others and some grew more than others). The labeling efficiency for strains B, C, E, and F were all approximately equal (2-10 CFU/DPM), while stain A was quite a bit different labeling at approximately 97 CFU/DPM. The estimated CFU was determined by taking the recorded DPM for each punch and multiplying it by the appropriate ratio. This gives the approximate CFU that attached. All data was converted from DPMs to estimated CFUs and then transformed to parametric data by taking the natural logarithm (LN) of each value. This transformation was used because the organisms grow in a geometric progression as they divide, and this is best represented by natural logarithms of the data. Statistical analyses and graphs were done on the LN transformed data.

Figure 1 is a graph showing divergent intestinal attachment affinity of 5 different MAP strains: (A=ATCC49164 isolate from a Crohn's disease patient, B=ATCC43015 isolate from a Crohn's disease patient, C=ATCC19698 isolate from the feces of a cow with naturally acquired MAP, E=UF7283B Low Pass Isolate, and F=strain E after modification of genetic expression.) to the intestine. All are statistically different from each other ($P < 0.0001$) except strains C and F ($P = .2184$).

Figure 2 is a graph relatively equivalent intestinal attachment of 5 different MAP strains within the gastrointestinal tract. There is no significant difference in the region of the intestine to which the organisms attached ($P = .5214$)

Figure 3 is a graph showing the effect of passage on intestinal attachment affinity of 3

different MAP strains (B=ATCC43015 isolate from a Crohn's disease patient. E=low passage of an oral vaccine candidate. F=strain E after modification of genetic expression.) Strains are statistically different from each other ($P=2.3210 \times 10^{-5}$)

Figure 4 is a graph showing the effect of passage on intestinal attachment location of 3 additional different MAP strains (B=ATCC43015 isolate from a Crohn's disease patient, E=UF7283B Low Pass Isolate, and F=strain E after modification of genetic expression.) to the 5 different regions of the intestine. Strains are not statistically different from each other ($P=.989144$).

Figure 5 is a graph showing the effect of fibronectin treatment on intestinal attachment affinity of 3 different MAP strains (B=ATCC43015 isolate from a Crohn's disease patient, E=UF7283B Low Pass Isolate of an oral vaccine candidate. F=Strain E after modification of genetic expression. Fibronectin treatment is on the right versus no treatment on the left. Strains B and F show no statistical difference in attachment between treatments ($P=.771063$ and $P=.331623$) respectively. Strain E is significantly different ($P=.009406$).

Figure 6 is a graph showing the effect of fibronectin treatment on divergent intestinal attachment location of 3 different MAP strains. B=ATCC43015. E=low passage of an oral vaccine candidate. F=strain E after modification of genetic expression. Strains did not show a significant difference in attachment to different regions of the bovine gastrointestinal tract (Strain B $P=.745992$; Strain E $P=.362609$; and Strain F $P=.766836$). Fibronectin treated samples versus untreated samples showed a significant difference in the mid-ileum ($P=.0087$) and lower-ileum ($P=.0096$).

Figure 7 is a histological photomicrograph of a sample of tissue from the colon

1 confirming mucosal presence of MAP.

2 Figure 8 is a histological photomicrograph of a sample of tissue from the lower ileum
3 confirming the presence of MAP within a goblet cell.

4 Characterization of MAP Binding Site with Field and Attenuated Strains:

5 Figures 5 and 6 present data from fibronectin treatment study. Fibronectin coating of the
6 organisms did not effect the attachment of the two high passage strains of MAP, but did affect
7 the binding of the low passage clinical isolate. The fibronectin treatment decreased the
8 attachment of the low passage clinical isolate to the calf gut epithelium (Figure 6). Fibronectin
9 treatment decreased attachment only in the mid ileum and the lower ileum.

10 Distribution of MAP Receptor Sites within the Bovine Gastrointestinal Tract.

11 The log CFU (colony forming unit) for the five strains is listed in Figure 1. The
12 CFU/DPM (colony forming unit/disintegration per minute) ratio was basically different for each
13 strain. Strain C attached to the same degree as strain F. For strains, B, C, E and F, the labeling
14 efficiency was approximately 2-10 CFU/DPM/ (Figure 2). Strain A, the inactivated oral vaccine
15 candidate was statistically different from the other strains studied ($P < .00001$). Its CFU/DPM
16 ratio was 97.

17 The live attenuated oral vaccine candidates exhibited relatively constant mucosal binding
18 despite serial in vitro passage in excess of 500 culture passages (Figure 2). Early passage strain
19 had a CFU/DPM ratio of 2 whereas that long-term passage strain had a CFU/DPM of 6. There
20 was no significant difference in the region of the gastrointestinal tract to which MAP attached
21 ($P = .5214$) as shown in Figure 2.

1 There was no statistical difference in the five intestinal sites studied. However, slightly
2 more organismal attachment occurred in the terminal ileum and colon.

3 Differences in Binding Affinities of MAP Isolates:

4 Results for this attachment study can be seen in Figures 1 through 8. The labeling
5 efficiencies for the different strains of the MAP varied among strains. By this it is meant that the
6 CFU/DPM ratio determined through plating each strain compared with the DPMs given for each
7 strain varied (i.e., some strains incorporated more radioactive material than others and some
8 grew more than others). The labeling efficiency for strains B, C, E, and F were all
9 approximately equal (2-10 CFU/DPM), while stain A was quite a bit different labeling at
10 approximately 97 CFU/DPM. The estimated CFU was determined by taking the recorded DPM
11 for each punch and multiplying it by the appropriate ratio. This gives the approximate CFU that
12 attached. All data was converted from DPMs to estimated CFUs and then transformed to
13 parametric data by taking the natural logarithm (LN) of each value. This transformation was
14 used because the organisms grow in a geometric progression as they divide, and this is best
15 represented by natural logarithms of the data. Statistical analyses and graphs were done on the
16 LN transformed data.

17 In each graph, LN of average estimated CFU is presented along the y-axis and MAP
18 strain or gut section is presented along the x-axis. In Figure 1 (data from experiment with 2
19 animals and no fibronectin treatment) the only comparison among strains that is not significantly
20 different is between strain C and F. In Figure 2 (same experiment) there is no significant
21 difference in the region to which the organisms attached. Figures 3 and 4 presents combined
22 data from all four animals in which no fibronectin treatment is used are shown. All three strains
23 of MAP attach differently from each other ($p < .001$), with the low passage clinical isolate

1 attaching less than the other two strains. However, there is not a significant difference in which
2 section of the intestine to which the organisms attach (Figure 4).

3 Figures 7 and 8 are pictures taken of tissue that was embedded in paraffin and sectioned
4 for acid fast staining. Figure 8 illustrates the normal morphology of the lower ileum, while 7
5 illustrates that of the colon. Figures 7 and 8 show the organisms in a goblet cell.

6 Certain modifications and improvements will occur to those skilled in the art upon a
7 reading of the foregoing description. All modifications and improvements have been deleted
8 herein for the sake of conciseness and readability but are properly within the scope of the
9 following claims.

10